BioSpace News Archive

Biopharma and life sciences companies provide updates on their pipelines and business plans.

Light-activated CRISPR technology edits genes more precisely and faster than the more standard chemical methods, and enables “super-fast” DNA repair, according to research from Johns Hopkins University School of Medicine.

New information released Tuesday by GlobalData showed that there are now more than 718 pipeline drugs associated with COVID-19. In addition, 70% of these products are in the discovery or preclinical stages.

Baltimore-based AsclepiX Therapeutics closed a $35 million Series A financing.

Speaking before Congress on Tuesday, Dr. Anthony Fauci urged people to adopt strategies that involve wearing a mask in public, maintaining social distance and avoiding large gatherings of people.

Yumanity Therapeutics and Merck signed a strategic research and license deal for two Yumanity programs.

COVID-19-related testimonies will continue in Congress today, with representatives from the Biotechnology Innovation Organization (BIO) expected to address the current pandemic as well as key priorities that will need to be in place in order to effectively respond to the next global viral threat.

Shares of Fulcrum Therapeutics were up more than 14% in premarket trading after the company announced it will begin the Phase LOSVID III study to assess losmapimod as a potential treatment of COVID-19.

Scientists at deCODE genetics, a subsidiary of Amgen, and their collaborators from the Icelandic healthcare system, University of Iceland and the Karolinska Institute in Sweden, today publish a study in Nature, comparing over 30 thousand patients with autoimmune thyroid disease from Iceland and UK with 725 thousand controls.

Many states have reopened amidst the COVID-19 pandemic, and elective surgeries are starting back up. As ambulatory surgery centers (ASCs) open their doors again, they are now tasked with figuring out how to update all of their infection prevention policies to keep staff and patients safe.